Gut bugs may hold key to immunotherapy response in bladder cancer

NCT ID NCT04566029

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed pilot study looked at whether the proteins produced by gut bacteria differ between bladder cancer patients who respond to immunotherapy and those who do not. Researchers collected stool and blood samples from 40 patients with advanced bladder cancer. The goal was to find a protein signature that could predict treatment response, potentially personalizing therapy and reducing unnecessary side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which bladder cancer patients will benefit from immunotherapy, avoiding unnecessary side effects and costs for non-responders.
What could go wrong: This is a small pilot study with only 40 participants, so results may not apply to all patients. It is exploratory and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CARCINOMA

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre Leon Berard

Lyon, 69373, France
HEGP GH Universitaire Paris Ouest

Paris, 75908, France
Hopital Tenon ( Paris)

Paris, Paris Cx 20, 75970, France
ICANS Strasbourg

Strasbourg, 67091, France
ICM parc euromedecine

Montpellier, Hérault, 34298, France
ICO-Site Paul Papin

Angers, 49055, France
Institut Bergonié

Bordeaux, 33076, France
Institut Sainte Cancerologie Lucien Neuwirth

Avignon, Saint Priest En Jarez, 42271, France
Iuct Oncopole

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.